MobiusHD for Hypertension

Phase-Based Progress Estimates
London Health Science Center, London, Canada
Hypertension+1 More
MobiusHD - Device
All Sexes
What conditions do you have?

Study Summary

This is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and benefit of the MobiusHD® system in renal hemodialysis subjects with uncontrolled hypertension.

Eligible Conditions

  • Hypertension
  • Uncontrolled Hypertension

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

6 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Change in 44-hour ambulatory blood pressure measurements (ABPM)
Change in Quality of Life (QoL), assessed by the Kidney Disease Quality of Life (KDQOL-36) questionnaire
Change in Quality of Life (QoL), assessed by the London Evaluation of Illness (LEVIL) questionnaire
Change in rate of blood pressure related hospitalizations
Incidence of intradialytic hypotension (IDH)
Major adverse neurological and cardiovascular events (MANCE)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

14 Total Participants · 1 Treatment Group

Primary Treatment: MobiusHD · No Placebo Group · N/A

Experimental Group · 1 Intervention: MobiusHD · Intervention Types: Device
First Studied
Drug Approval Stage
How many patients have taken this drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: London Health Science Center · London, Canada
2006First Recorded Clinical Trial
2 TrialsResearching Hypertension
15 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be between the ages of 21 and 75 years.
You have hypertension that is unresponsive to medical therapy of at least 3 anti-hypertensive medication classes.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.